# Study Examining The Effect Of Hepatic Impairment On Safety, Toleration And How The Body Processes An Experimental Drug

> **NCT00645021** · PHASE1 · COMPLETED · sponsor: **Pfizer** · enrollment: 24 (actual)

## Conditions studied

- Obesity
- Hepatic Insufficiency

## Interventions

- **DRUG:** CP-945,598
- **DRUG:** CP-945,598
- **DRUG:** CP-945,598

## Key facts

- **NCT ID:** NCT00645021
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-04
- **Primary completion:** 2008-10
- **Final completion:** 2008-10
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2009-08-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00645021

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00645021, "Study Examining The Effect Of Hepatic Impairment On Safety, Toleration And How The Body Processes An Experimental Drug". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00645021. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*